KYNTRA BIO, INC. (KYNB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$6.67

From 52W high−42.85%

Volume79861.00

Market cap$28.65M

P/E (TTM)0.1x

P/S (TTM)6.2x

Div yield—

Key dataSep 18, 2026

Open

$6.67

From 52W high

−42.85%

Volume

79861.00

Market cap

$28.65M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.4x

P/E (TTM)

0.1x

RSI (14)

35.0

MomentumView details →

1D Return

−0.35%

YTD Return

−20.39%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

0.1x

EV/EBITDA

0.4x

EV/Sales

−8.8x

P/S (TTM)

6.2x

P/B (TTM)

−1.0x

ProfitabilityView details →

Gross Margin

18.15%

Net Margin

3967.77%

EBITDA Margin

−2036.13%

ROE (TTM)

−607.72%

ROA (TTM)

181.24%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

+106.34%

EPS YoY

+3782.91%

FCF YoY

−60.65%

Revenue CAGR 3Y

−64.23%

EPS CAGR 3Y

+9552.08%

EBITDA YoY

+27.16%

MomentumView details →

1D Return

−0.35%

YTD Return

−20.39%

1Y Return

−38.20%

RSI (14)

35.0

vs 50D SMA

−5.87%

vs 200D SMA

−7.41%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

2.69x

Quick Ratio

2.59x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$2.96

EPS Surprise

193.08%

Beats (12Q)

4/12

Next Q EPS Est

−$3.66

Avg Surprise (4Q)

47.21%

Rev Surprise

−171.78%

Financials snapshotView financials →

Revenue (TTM)

4.62M

Net Income (TTM)

183.19M

Op. CF (TTM)

−38.05M

Next earningsNov 9, 2026 →

Latest newsMore news →

Kyntra Bio signed an amendment and restatement of its royalty financing agreement with NQ Project Phoebus, L.P., materially reducing its payment obligations in exchange for an accelerated upfront payment.20d ago

Kyntra Bio reported its financial results for the second quarter of 2026.38d ago

Similar companies

Sanai Health Industry Group Company Limited01889.HK Pa Shun International Holdings Limited00574.HK 111, Inc.YI LifeMD, Inc.LFMDP PetMed Express, Inc.PETS AIxCrypto Holdings, Inc.AIXC Find similar companies →

Latest newsMore news →

Kyntra Bio signed an amendment and restatement of its royalty financing agreement with NQ Project Phoebus, L.P., materially reducing its payment obligations in exchange for an accelerated upfront payment.20d ago Kyntra Bio reported its financial results for the second quarter of 2026.38d ago